946826-47-7

Basic information

• Product Name: Acetamide, N-(3-amino-2,6-difluorophenyl)-
• Synonyms: Acetamide, N-(3-amino-2,6-difluorophenyl)-;N-(3-aMino-2,6-difluorophenyl)acetaMide
• CAS NO: 946826-47-7
• Molecular Formula: C₈H₈F₂N₂O
• Molecular Weight: 186.16
• Mol File: 946826-47-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: Acetamide, N-(3-amino-2,6-difluorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-(3-amino-2,6-difluorophenyl)-(946826-47-7)
• EPA Substance Registry System: Acetamide, N-(3-amino-2,6-difluorophenyl)-(946826-47-7)

Safety Data

• Hazardous Substances Data: 946826-47-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Acetamide, N-(3-amino-2,6-difluorophenyl)is used as a building block for the synthesis of pharmaceutical compounds due to its unique structural features, including the presence of fluorine atoms which can influence the pharmacokinetic and pharmacodynamic properties of the resulting drugs.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, Acetamide, N-(3-amino-2,6-difluorophenyl)is utilized as a starting material for the development of new agrochemicals, potentially enhancing the effectiveness of pesticides or other agricultural chemicals through the incorporation of its specific chemical structure.
Used in Research Applications:
Acetamide, N-(3-amino-2,6-difluorophenyl)is also used as a research chemical for studying the biological and chemical properties of fluorinated organic compounds, which can provide insights into their reactivity, stability, and interactions with biological systems.

Upstream product

• 5509-65-9 2,6-difluoroaniline 
• 25892-08-4 N-(2,6-difluoro-3-nitrophenyl)acetamide 
• 3896-29-5 N-(2,6-difluorophenyl)acetamide 

Downstream Products

• 1383745-37-6 N-(2,6-difluoro-3-(propylsulfonamido)phenyl)acetamide 
• 1383745-19-4 C₉H₁₂F₂N₂O₂S*ClH 
• 1103234-57-6 N-(3-amino-2,4-difluorophenyl)propane-1-sulfonamide 
• 1392429-92-3 N-(2,4-difluoro-3-iodophenyl) propane-1-sulfonamide 
• 1392429-79-6 N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin- 1-yl)-2,4-difluorophenyl)propane-1-sulfonamide 
• 1380229-14-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)benzenesulfonamide 
• 1269421-42-2 N-(3-amino-2,4-difluorophenyl)benzenesulfonamide 
• 1380228-88-5 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)9H-purin-6-yl)pyridin-2-ylamino)phenyl)cyclohexanesulfonamide 
• 1380228-96-5 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)9H-purin-6-yl)pyridin-2-ylamino)phenyl)cyclopropansulfonamide 
• 1380228-67-0 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)propan-2-sulfonamide 
• 1380228-66-9 N-(3-amino-2,4-difluorophenyl)propane-2-sulfonamide 
• 1380228-80-7 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)propane-1-sulfonamide 
• 1380228-78-3 N-(2,4-difluoro-3-(3-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)pyridin-2-ylamino)phenyl)thiophene-2-sulfonamide 
• 1380228-53-4 N-(3-(3-(9H-purin-6-yl)pyridin-2-ylamino)-2,4-difluorophenyl)benzenesulfonamide 

Relevant articles and documents

CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR

The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.

Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling

One of the challenges for targeting B-RafV600E with small molecule inhibitors had been achieving adequate selectivity over the wild-type protein B-RafWT, as inhibition of the latter has been associated with hyperplasia in normal tissues. Recent studies suggest that B-Raf inhibitors inducing the 'DFG-in/αC-helix-out' conformation (Type IIB) likely will exhibit improved selectivity for B-RafV600E. To explore this hypothesis, we transformed Type IIA inhibitor (1) into a series of Type IIB inhibitors (sulfonamides and sulfamides 4-6) and examined the SAR. Three selectivity indices were introduced to facilitate the analyses: the B-RafV600E/B-RafWT biochemical (bS), cellular (cS) selectivity, and the phospho-ERK activation (pA). Our data indicates that α-branched sulfonamides and sulfamides show higher selectivities than the linear derivatives. We rationalized this finding based on analysis of structural information from the literature and provided evidence for a monomeric B-Raf-inhibitor complex previously hypothesized to be responsible for the desired B-RafV600E selectivity.

PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R6, A, X, Y and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A,X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

NEW AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R6, A, X, Y and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

NEW PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I), wherein the groups R2 to R4 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A, X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.